Insurers see higher unit costs and increased utilization while HHS examines premium hikes
The good news in January from the Office of the Actuary at the Centers for Medicare and Medicaid Services (CMS) is that U.S. health expenditures remained flat for 2011, rising 3.9% to $2.7 trillion in annual health outlays. That growth still exceeds current inflation rates, and it’s low largely because of lingering effects of the recession.
Health and Human Services (HHS) secretary Kathleen Sebelius credits provisions in the Patient Protection and Affordable Care Act (PPACA) for limiting outlays, pointing to its success in holding down private health insurance premiums, which rose only 3.8% in 2011. Analysts note impact from PPACA’s medical loss ratio provision and required coverage of dependents under age 26 boosted enrollment in private plans by 1 million-largely young, healthy individuals that helped maintain low per-person expenditures.
The broader impact of PPACA expenditures and savings won’t be apparent until next year. Another CMS study predicts that in 2014, healthcare spending will surge by 7.4% as millions gain coverage. Consumers already face higher out-of-pocket costs as employers seek to limit healthcare spending, a factor boosting worker enrollment in consumer-directed health plans, up from 8% in 2008 to 17% in 2011.
Premiumsandcosts
In anticipation of these changes, insurers are seeking higher premiums on individual and small group policies for 2013, generating complaints from Sebelius and state regulators. Insurers complain that higher medical costs and a new $8 billion PPACA fee are driving up the cost of coverage. The authorities challenge moves to boost premiums this year to cover anticipated costs for 2014.
Recently, a rate request from Blue Cross of California was opposed because it was unreasonable to charge customers for fees not due for a year. Aetna, UnitedHealth and others have proposed similar double-digit increases for individual and small market coverage, partly to avoid bigger rate spikes next year.
Insurers seek to explain their actions with data highlighting cost factors underlying rising premiums. An Oliver Wyman study funded by America’s Health Insurance Plans (AHIP) examines how PPACA age rating restrictions will boost premiums for young adults, especially those that don’t qualify for premium assistance.
Such research will help insurers influence the upcoming debate on healthcare cost cutting, which will build on the tax relief act approved by Congress January 1 to postpone major budget cuts and tax hikes. That legislation delayed a 26.5% reduction in Medicare rates for doctors, covering some of the $25 billion cost through “adjustments” in Medicare pay to hospitals, more intense review of coding by Medicare Advantage plans and other program revisions.
The need for further budget cuts could build support for more Medicare means testing, a higher eligibility age, curbs on Medi-gap first-dollar coverage and tighter rates for MA plans.
There is no shortage in cost-cutting proposals. UnitedHealth Group predicts big savings from better coordination of care for patients with chronic diseases. The Kaiser Family Foundation recently unveiled a list of 150 policy options with potential for reducing Medicare spending. Like healthcare interest groups, insurers are looking for cuts to protect their funding streams.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
Inflation Reduction Act: Reforms to Patient Cost-Sharing
September 18th 2023Lower out-of-pocket costs for patients might put upward pressure on drug prices, as manufacturers face less price sensitivity, note Matthew Majewski and Rhett Johnson of Charles River Associates. But they also note that upward pressure on price is likely to be limited to the inflation rate as any additional price increase would need to be paid back to CMS in the form of inflation rebates.
Read More
Spending climbed by 2.7% in 2021. In 2020, it soared by 10.3%, fueled by federal government spending in response to the pandemic. The blizzard of calculations of 2021 healthcare spending by CMS’ actuaries also provides further evidence that utilization of healthcare services bounced back in 2021.
Read More
Talking PIE, the Act, Before Thanksgiving
November 23rd 2022AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Read More
Inflation Reduction Act and the Impact on Pharmaceutical Pricing and Investment Decisions
November 21st 2022The reference to “maximum fair price” in the act bodes poorly for manufacturers and suggests more of a take-it-or-leave-it situation rather than a negotiation where clinical evidence would be the prevailing factor in determining price.
Read More
2 Clarke Drive
Cranbury, NJ 08512